Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D-CFTR mutation.
about
Potentiators (specific therapies for class III and IV mutations) for cystic fibrosisPotentiator ivacaftor abrogates pharmacological correction of ΔF508 CFTR in cystic fibrosis.Repeatability and Diagnostic Value of Nasal Potential Difference in a Genetically Admixed Population.Activation of the Endogenous Renin-Angiotensin-Aldosterone System or Aldosterone Administration Increases Urinary Exosomal Sodium Channel ExcretionCombination therapy with cystic fibrosis transmembrane conductance regulator modulators augment the airway functional microanatomy.Moderate intensity exercise mediates comparable increases in exhaled chloride as albuterol in individuals with cystic fibrosis.Novel outcome measures for clinical trials in cystic fibrosisAirway Mucosal Host Defense is Key to Genomic Regulation of Cystic Fibrosis Lung Disease Severity.Biomarkers for cystic fibrosis drug development.Individualized medicine using intestinal responses to CFTR potentiators and correctors.A multiple reader scoring system for Nasal Potential Difference parameters.Use of ferrets for electrophysiologic monitoring of ion transport.Toward inclusive therapy with CFTR modulators: Progress and challenges.l-Methionine anti-biofilm activity against Pseudomonas aeruginosa is enhanced by the cystic fibrosis transmembrane conductance regulator potentiator, ivacaftor.Ion Channel Modulators in Cystic Fibrosis
P2860
Q24187139-913A61DB-355A-492E-97EA-8EF6A4CC78A0Q34748891-B719E6E1-31F2-439E-8233-020A6B2EC43FQ36364754-8A113867-C904-4CFD-936E-0383975EDE43Q36514922-8F899FAA-611F-4F30-892B-B789CE582824Q36976621-5B12B0AE-6ADC-4FB7-97F9-9866BC043661Q37087501-4909156B-42FA-422E-BF2F-4406A8C5FE7FQ38340406-4D58EE75-361A-47F6-9B60-C6410981CD8BQ38602344-AD64367D-AD83-4FEF-825B-B53E1B57A7DCQ38755600-8427FA64-C1EC-4DDC-A17C-96F70D89354EQ38962735-5C1FB396-8FA7-4475-A812-7217DC5F11ABQ46566814-20941343-7780-4B41-BEDF-CB0C9F4C1DDDQ46766337-A52B1136-871D-4D8C-9854-AB10008AC951Q47842086-C16FA91E-112F-45A9-94E3-7F098C505C55Q50141673-85DFD2D7-D29D-45C4-BF05-0DD4DBD5B34AQ56966061-21BB3797-4695-4D1E-83D7-2B5BAB511111
P2860
Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D-CFTR mutation.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Optimizing nasal potential dif ...... with the G551D-CFTR mutation.
@ast
Optimizing nasal potential dif ...... with the G551D-CFTR mutation.
@en
Optimizing nasal potential dif ...... with the G551D-CFTR mutation.
@nl
type
label
Optimizing nasal potential dif ...... with the G551D-CFTR mutation.
@ast
Optimizing nasal potential dif ...... with the G551D-CFTR mutation.
@en
Optimizing nasal potential dif ...... with the G551D-CFTR mutation.
@nl
prefLabel
Optimizing nasal potential dif ...... with the G551D-CFTR mutation.
@ast
Optimizing nasal potential dif ...... with the G551D-CFTR mutation.
@en
Optimizing nasal potential dif ...... with the G551D-CFTR mutation.
@nl
P2093
P2860
P1433
P1476
Optimizing nasal potential dif ...... with the G551D-CFTR mutation.
@en
P2093
Anne J Stone
Aubrey Hill
Claudia L Ordoñez
Eric R Olson
Frank J Accurso
Heather Hathorne
John P Clancy
John R Beamer
Morty Cohen
P2860
P304
P356
10.1371/JOURNAL.PONE.0066955
P407
P577
2013-07-26T00:00:00Z